Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI® (autologous cultured chondrocytes on porc ...